Your browser is no longer supported. Please, upgrade your browser.
We’ve redesigned our maps and bubbles! Read more about the new features here. ×
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 70 #1
TickerCVSL [AMEX]
CompanyCVSL Inc.
CountryUSA
IndustryMarketing Services
Market Cap121.44MEPS (ttm)-0.50
P/E-EPS this Y-84.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-16.90%
P/S1.27EPS next 5Y-
P/B-EPS Q/Q-266.70%
Dividend-Sales Q/Q12.00%
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float0.11%Earnings-
Analyst Recom-Target Price-
Avg Volume13.65K52W Range4.23 - 19.85
Feb-27-15 04:25AM4:25 am CVSL prices its previously announced public offering of shares, which now includes warants; gross proceeds are expected to be $20 mln Briefing.com
Feb-26-15 08:37PMCVSL Announces Pricing Of Public Offering Of $20,000,000 Of Securities PR Newswire
Feb-26-15 08:22PMCVSL Announces Update To Proposed Public Offering Of Securities PR Newswire
Feb-24-15 05:05PMCVSL Announces Proposed Public Offering of Common Stock PR Newswire
Feb-06-15 06:05AMCVSL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhi EDGAR Online
Feb-06-15 04:30AMCVSL Signs Agreement To Acquire Kleeneze PR Newswire
Jan-16-15 02:43PMCVSL To Hold Investor Information Call On January 21 PR Newswire
Dec-03-14 06:01PMCVSL Files S-3 Shelf Registration Statement PR Newswire
Dec-03-14 04:13PMCVSL INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online
Dec-03-14 03:28PMCVSL Inc. Will Begin Trading On New York Stock Exchange This Friday PR Newswire
TickerQTWO [NYSE]
CompanyQ2 Holdings, Inc.
CountryUSA
IndustryBusiness Software & Services
Market Cap734.44MEPS (ttm)-0.81
P/E-EPS this Y-21.80%
Forward P/E-EPS next Y17.80%
PEG-EPS past 5Y0.00%
P/S9.28EPS next 5Y-
P/B9.18EPS Q/Q30.00%
Dividend-Sales Q/Q40.80%
Insider Own2.60%Inst Own43.30%
Insider Trans-28.64%Inst Trans70.89%
Short Float3.00%EarningsFeb 05/a
Analyst Recom1.70Target Price22.08
Avg Volume113.07K52W Range9.62 - 21.96
Feb-27-15 04:30AM4:30 am Q2 Holdings prices its upsized public offering of 5,122,353 shares at a price to the public of $19.75 per share; Q2 is selling 1.5 mln shares in the offering and selling stockholders are selling 3,622,353 shares Briefing.com
Feb-26-15 09:24PMQ2 Holdings, Inc. Announces the Upsizing and Pricing of Follow-on Offering of Common Stock Business Wire
Feb-26-15 05:12PMQ2 HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-23-15 04:48PMQ2 Holdings, Inc. Announces Launch of Proposed Follow-on Offering of Common Stock Business Wire
Feb-19-15 01:04PMQ2 HOLDINGS, INC. Financials EDGAR Online Financials
Feb-12-15 05:23PMQ2 HOLDINGS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Feb-09-15 08:30AMQ2 Holdings (QTWO) Worth a Look: Stock Rises 5.4% - Tale of the Tape Zacks
Feb-05-15 04:17PMQ2 HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
Feb-05-15 04:05PMQ2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2014 Financial Results Business Wire
Feb-05-15 07:07AMQ4 2014 Q2 Holdings Inc Earnings Release - After Market Close CCBN
TickerCYCC [NASD]
CompanyCyclacel Pharmaceuticals, Inc.
CountryUSA
IndustryBiotechnology
Market Cap25.11MEPS (ttm)-0.88
P/E-EPS this Y26.30%
Forward P/E-EPS next Y4.20%
PEG-EPS past 5Y38.20%
P/S13.95EPS next 5Y-
P/B1.01EPS Q/Q31.30%
Dividend-Sales Q/Q133.30%
Insider Own7.47%Inst Own7.90%
Insider Trans0.18%Inst Trans-4.46%
Short Float3.70%EarningsMar 24/a
Analyst Recom2.50Target Price9.00
Avg Volume342.64K52W Range0.51 - 4.14
Feb-20-15 05:12PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events EDGAR Online
Feb-06-15 04:22PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule EDGAR Online
Feb-03-15 07:00AMCyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference GlobeNewswire
Jan-06-15 07:00AMCyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference GlobeNewswire
Dec-16-14 08:17AMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Dec-16-14 07:00AMCyclacel Announces Enrollment of 486 Patients, DSMB Recommendations and That the Seamless Phase 3 Trial of Sapacitabine in AML Will Continue to Final Analysis GlobeNewswire
Dec-04-14 04:28PMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events EDGAR Online
Nov-21-14 01:04PMCYCLACEL PHARMACEUTICALS, INC. Financials EDGAR Online Financials
Nov-12-14 09:12AMCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement EDGAR Online
Oct-13-14 06:30AMExact Sciences (EXAS) Looks Strong: Stock Surges 35.8% Zacks
TickerMGT [AMEX]
CompanyMGT Capital Investments, Inc.
CountryUSA
IndustryMultimedia & Graphics Software
Market Cap5.43MEPS (ttm)-0.70
P/E-EPS this Y29.80%
Forward P/E-EPS next Y-
PEG-EPS past 5Y38.00%
P/S6.03EPS next 5Y-
P/B0.51EPS Q/Q65.90%
Dividend-Sales Q/Q642.50%
Insider Own21.54%Inst Own19.90%
Insider Trans0.00%Inst Trans3.83%
Short Float2.02%Earnings-
Analyst Recom-Target Price2.00
Avg Volume73.99K52W Range0.47 - 2.75
Feb-27-15 08:02AM8:02 am MGT Capital Investments to merge with bitcoin derivatives exchange owner Tera Group Briefing.com
Feb-27-15 08:00AMMGT Capital Investments to Merge with Tera Group PR Newswire
Jan-28-15 06:42PMMGT And Vivid Celebrate The Launch Of Daily Fantasy Sports Site VividBetSports.com With Party At Vivid Cabaret NYC On Saturday, January 31st PR Newswire
Jan-13-15 09:00AMMGT Capital Provides Update of Patent Litigation Against Aruze Gaming USA PR Newswire
Jan-08-15 09:48AMMGT Capital to Present at the 11th Annual Noble Financial Capital Markets Equity Conference January 20, 2015 PR Newswire
Dec-30-14 08:45AMMGT and Vivid Entertainment Team Up to Introduce Daily Fantasy Sports Site PR Newswire
Dec-30-14 08:08AMAdult Entertainment Company Vivid Partners With Fantasy Sports Platform at Forbes
Dec-29-14 08:10AMMGT CAPITAL INVESTMENTS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
Dec-23-14 09:00AMMGT Featured in Article on the Rapidly Growing Daily Fantasy Sports Industry PR Newswire
Dec-18-14 02:57PMDaily Fantasy Sports Makes Its Way To Facebook at Forbes
TickerWTW [NYSE]
CompanyWeight Watchers International, Inc.
CountryUSA
IndustryPersonal Services
Market Cap995.48MEPS (ttm)2.55
P/E6.89EPS this Y-14.20%
Forward P/E12.31EPS next Y-29.43%
PEG-EPS past 5Y6.90%
P/S0.65EPS next 5Y-
P/B-EPS Q/Q-37.40%
Dividend-Sales Q/Q-12.90%
Insider Own0.20%Inst Own-
Insider Trans0.00%Inst Trans4.84%
Short Float29.12%EarningsFeb 26/a
Analyst Recom3.20Target Price24.33
Avg Volume878.49K52W Range16.40 - 29.84
Feb-27-15 09:35AMStocks to Watch: J.C. Penney, Icahn Enterprises, Weight Watchers at The Wall Street Journal
Feb-27-15 08:58AMOld Navy boosts The Gap; J.C. Penney disappoints; Weight Watchers' thin forecast Yahoo Finance
Feb-27-15 08:04AMStocks Fab February; Nasdaq 5000?; GDP in focus; Weight Watchers woes Yahoo Finance
Feb-27-15 08:00AMEarly movers: FDX, TMUS, CSX, MNST, JCP & more at CNBC
Feb-27-15 12:26AM[$$] Weight Watchers Loses Money, Members at The Wall Street Journal
Feb-26-15 05:54PMWeight Watchers reports 4Q loss AP
Feb-26-15 05:24PMAfter-hours buzz: JC Penney, Herbalife, Gap & more at CNBC
Feb-26-15 04:31PMUpdates, advisories and surprises at MarketWatch
Feb-26-15 04:16PMWeight Watchers' stock tumbles after profit outlook falls well short of estimates at MarketWatch
Feb-26-15 04:14PM4:14 pm Weight Watchers reports EPS in-line, misses on revs; guides FY15 EPS below consensus Briefing.com
TickerACUR [NASD]
CompanyAcura Pharmaceuticals, Inc.
CountryUSA
IndustryDrug Delivery
Market Cap37.16MEPS (ttm)-0.28
P/E-EPS this Y-45.00%
Forward P/E-EPS next Y29.00%
PEG-EPS past 5Y-24.60%
P/S123.85EPS next 5Y-
P/B4.75EPS Q/Q14.30%
Dividend-Sales Q/Q0.00%
Insider Own0.40%Inst Own48.30%
Insider Trans-46.65%Inst Trans0.28%
Short Float0.18%EarningsMar 02/a
Analyst Recom2.50Target Price1.00
Avg Volume118.91K52W Range0.41 - 2.12
Feb-27-15Upgrade MLV & Co Hold → Buy $1
Feb-27-15 06:33AMAcura Pharma upgraded by MLV & Co Briefing.com
Feb-23-15 06:30AMAcura Pharmaceuticals to Host 2014 Financial Results Conference Call on March 3, 2015 Marketwired
Feb-16-15 06:30AMAcura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations Marketwired
Feb-05-15 06:15AMAcura Pharmaceuticals Expands Meth-Resistant Decongestant Line With NEXAFED(R) Sinus Pressure + Pain Marketwired
Jan-08-15 06:31AMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online
Jan-08-15 06:00AMAcura Pharmaceuticals Partners With Egalet Corporation to Commercialize Immediate Release Oxycodone Product Utilizing Acura's Aversion(R) (Abuse-Deterrent) Technology Marketwired
Dec-23-14 04:01PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Other Events EDGAR Online
Dec-23-14 06:00AMAcura Pharmaceuticals Acknowledges Distribution of Nexafed(R) by Kmart Pharmacy Marketwired
Dec-12-14 11:09AMACURA PHARMACEUTICALS, INC Files SEC form 8-K/A, Change in Directors or Principal Officers EDGAR Online
Dec-11-14 04:03PMACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
TickerCYTX [NASD]
CompanyCytori Therapeutics, Inc.
CountryUSA
IndustryBiotechnology
Market Cap104.37MEPS (ttm)-0.54
P/E-EPS this Y29.10%
Forward P/E-EPS next Y37.00%
PEG-EPS past 5Y19.00%
P/S14.30EPS next 5Y-
P/B-EPS Q/Q-50.00%
Dividend-Sales Q/Q-59.30%
Insider Own0.80%Inst Own19.00%
Insider Trans12.14%Inst Trans-12.86%
Short Float10.79%EarningsMar 10/a
Analyst Recom2.30Target Price5.67
Avg Volume2.51M52W Range0.36 - 3.33
Feb-26-15 08:01AM8:01 am Cytori Therapeutics announces it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States Briefing.com
Feb-26-15 08:00AMFDA Approves Expansion of Pivotal Scleroderma STAR Trial to 20 Clinical Sites Business Wire
Feb-24-15 08:00AMCytori Receives Positive European Opinion on Orphan Drug Status Business Wire
Feb-19-15 08:51AMCytori Therapeutics (CYTX) Worth Watching: Stock Up 25.5% - Tale of the Tape Zacks
Feb-17-15 08:00AMCytori Begins Enrollment in ACT-OA: US Phase II Trial for Knee Osteoarthritis Business Wire
Feb-10-15 08:00AMEnrollment Begins European Knee Meniscus Injury Pilot Trial to Evaluate Cytori Cell Therapy Business Wire
Jan-20-15 04:15PMCytori and Leading Expert Discuss Importance of STAR Trial and Treatment for Scleroderma Patients Business Wire
Jan-12-15 04:16PMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Jan-12-15 08:00AMFDA Approves Cytori U.S. Pivotal Scleroderma Trial Business Wire
Jan-08-15 06:00AMCYTORI THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
TickerROVI [NASD]
CompanyRovi Corporation
CountryUSA
IndustryMultimedia & Graphics Software
Market Cap2.11BEPS (ttm)0.02
P/E1147.00EPS this Y205.00%
Forward P/E9.50EPS next Y39.90%
PEG88.23EPS past 5Y4.30%
P/S3.76EPS next 5Y13.00%
P/B1.79EPS Q/Q-216.70%
Dividend-Sales Q/Q4.10%
Insider Own0.50%Inst Own93.00%
Insider Trans-2.79%Inst Trans-2.32%
Short Float5.08%EarningsFeb 19/a
Analyst Recom2.40Target Price27.69
Avg Volume600.24K52W Range17.52 - 25.24
Feb-27-15 08:53AMWeakness Seen in Rovi (ROVI): Stock Falls by 5.3% - Tale of the Tape Zacks
Feb-27-15 04:48AM4:48 am Rovi prices $300 mln principal amount of 0.500% Convertible Senior Notes due 2020 in a private offering Briefing.com
Feb-27-15 04:34AMRovi Corporation Announces Pricing of $300 Million in Convertible Senior Notes Business Wire
Feb-26-15 01:04PMROVI CORP Financials EDGAR Online Financials
Feb-25-15 04:15PMRovi Corporation Announces Plans to Offer $300 Million in Convertible Senior Notes Business Wire
Feb-25-15 12:35AMRovi Ready to Rev Up at Barrons.com
Feb-21-15 07:08PM10-K for Rovi Corp. Company Spotlight
Feb-20-15 05:14PMROVI CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
Feb-19-15 04:42PMRovi reports 4Q loss AP
Feb-19-15 04:07PMROVI CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
TickerMOSY [NASD]
CompanyMoSys, Inc.
CountryUSA
IndustrySemiconductor - Integrated Circuits
Market Cap100.58MEPS (ttm)-0.66
P/E-EPS this Y-20.00%
Forward P/E-EPS next Y95.80%
PEG-EPS past 5Y-1.60%
P/S18.63EPS next 5Y30.00%
P/B2.04EPS Q/Q-38.50%
Dividend-Sales Q/Q10.00%
Insider Own3.00%Inst Own41.30%
Insider Trans3.46%Inst Trans-3.20%
Short Float5.85%EarningsJan 30/b
Analyst Recom2.00Target Price4.50
Avg Volume143.25K52W Range1.49 - 5.35
Feb-27-15 08:50AMMoSys Prices Underwritten Public Offering of Common Stock Business Wire
Feb-27-15 08:50AM8:50 am MoSys priced its underwritten public offering of 12.5 mln shares of its common stock at a price of $1.60 per share Briefing.com
Feb-26-15 04:05PMMoSys Announces Proposed Public Offering of Common Stock Business Wire
Feb-25-15 09:05AMMoSys to Present Data Center Workload Acceleration with 25G Ethernet at the Linley Tech Data Center Conference 2015 Business Wire
Jan-30-15 08:30AMMoSys Inc Earnings Call scheduled for 8:30 am ET today CCBN
Jan-30-15 07:52AMMoSys reports 4Q loss AP
Jan-30-15 07:51AMMOSYS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
Jan-30-15 07:30AMMoSys, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results Business Wire
Jan-30-15 07:07AMQ4 2014 MoSys Inc Earnings Release - Before Market Open CCBN
Jan-28-15 09:00AMMoSys to Showcase Serial Packet Processor Offload Engines with FPGA and 100G Low Power CDR Products Enabling Added Throughput, Density, and Intelligence for Networking Systems from 100G to Terabit per Second at DesignCon 2015 Business Wire
TickerABTL [NASD]
CompanyAutobytel Inc.
CountryUSA
IndustryInternet Information Providers
Market Cap93.73MEPS (ttm)3.34
P/E3.11EPS this Y-7.40%
Forward P/E22.57EPS next Y84.00%
PEG0.12EPS past 5Y18.90%
P/S0.93EPS next 5Y25.00%
P/B1.35EPS Q/Q-23.10%
Dividend-Sales Q/Q26.90%
Insider Own0.50%Inst Own54.80%
Insider Trans51.48%Inst Trans-2.98%
Short Float0.78%EarningsFeb 26/a
Analyst Recom2.00Target Price15.33
Avg Volume71.03K52W Range7.90 - 16.60
Feb-26-15 08:07PMAutobytel posts 4Q profit AP
Feb-26-15 05:24PMPriceline (PCLN) Prices EUR 1B Unsecured Senior Notes - Analyst Blog Zacks
Feb-26-15 04:45PMAUTOBYTEL INC Files SEC form 10-K, Annual Report EDGAR Online
Feb-26-15 04:20PM4:20 pm Autobytel beats by $0.19, reports revs in-line; guides FY15 EPS above consensus, revs in-line Briefing.com
Feb-26-15 04:05PMAutobytel Reports Fourth Quarter and Full Year 2014 Results GlobeNewswire
Feb-26-15 07:07AMQ4 2014 Autobytel Inc Earnings Release - After Market Close CCBN
Feb-25-15 05:36PMInaugural Books from Amazon Kindle Scout Next Week - Analyst Blog Zacks
Feb-25-15 05:13PMIs Amazon Considering Distribution Center in Shakopee? - Analyst Blog Zacks
Feb-25-15 09:15AMCan The Uptrend Continue for Autobytel (ABTL)? - Tale of the Tape Zacks
Feb-24-15 06:40PMFotoNation Buys Smart Sensors for Biometric Capabilities - Analyst Blog Zacks
1 2 3 4 5 6 7 next